Clinical Trial Update: A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) [Phase 3]

View source ↗

Summary

A Phase 3b, open-label study evaluating durvalumab plus gemcitabine-based chemotherapy as first-line treatment for unresectable biliary tract cancers in Chinese…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: AstraZeneca | Conditions: Biliary Tract Cancers | Phase 3 | Status: COMPLETED